The legal industry has been left permanently altered from the pandemic. Five thought leaders provide their exclusive take into what these changes look like from the inside
While WTO member states have expressed general sympathy for the goal to provide broad access to vaccine technology during the pandemic, Germany continues to favour patent protection over compulsory licensing.
The German biotech company becomes the second mRNA vaccine maker to say it will not take legal action during pandemic
21 February 2022
Rigorous correlation analysis makes the case that IP rights are not the barrier to vaccine and treatment access that advocates claim, argues David Torstensson
16 February 2022
Petro Terblanche tells IAM about the IP issues surrounding her team’s new replica of Moderna’s covid-19 vaccine
10 February 2022
African tech transfer hub is making fast progress in replicating the approved mRNA jab
18 January 2022
IAM’s Global Leaders provide the inside scoop on some of the biggest difficulties they are helping their clients navigate, from patent eligibility to labour shortages
13 December 2021
A post-Merkel change of approach by the country’s recently agreed traffic light coalition government could change the momentum of TRIPS suspension talks – but don’t bet on it
07 December 2021
Arbutus Biopharma’s shares soar in anticipation of mRNA jab royalty lawsuit after Federal Circuit ruling
03 December 2021
IAM readers have their say on the quality, service and value delivered by patent offices in China, Europe, Japan, South Korea and the United States
29 November 2021
29 November 2021
29 November 2021
Unlock unlimited access to all IAM content
